Atiprimod (azaspirane, SK&F106615)
Published: Oct 15, 2008 8:00 am
| Brand Name: | Atiprimod |
| Generic Name: | azaspirane |
| Code Name: | SK&F106615 |
| Company: | Callisto Pharmaceuticals |
| FDA Clinical Phase: | 1/2 |
Description:
A substance being studied in the treatment of certain multiple myelomas and other advanced cancers. Atiprimod may block the growth of tumors and the growth of new blood vessels that tumors need to grow. Atiprimod is a type of signal transduction inhibitor.
Clinical Trials:
Currently, there are no open clinical trials studing Atiprimod for multiple myeloma.
Source: NCI Cancer Glossary, Atiprimod, http://www.cancer.gov/templates/db_alpha.aspx?searchTxt=Atiprimod (as of November 14, 2009)
Related Articles:
- Beacon NewsFlashes – July 23, 2010
- Phase 1 Clinical Trial Of CX-4945 Begins In Cancer Patients
- Onyx Pharmaceuticals To Acquire Proteolix, Developer Of Carfilzomib
- Prolexys Pharmaceuticals Raises $20 Million to Further Work on Anti-tumor Molecule
- New Clinical Trials Combine Zolinza And Velcade For Multiple Myeloma Treatment
Leave a comment